Matthew Angel - 04 Feb 2026 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)

Reporting relationship: CEO and President, Director, 10%+ Owner
Issuer ticker: TPST
Reported as of: 04 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2026, 16:26:13 UTC
Prior SEC filing: 06 Feb 2026
Next SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Angel

Key filing fact

Matthew Angel filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 06 Feb 2026.

Key facts

This page summarizes Matthew Angel's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 16:26.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001931356 Primary reporting owner

Angel Matthew

Relationship: CEO and President, Director, 10%+ Owner
Address: C/O TEMPEST THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE
Signature: /s/ Matthew Angel
Signature date: 06 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TPST transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +269,621
Change %
Price: $0.000000
Shares after: 269,621
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 269,621
Exercise price: $2.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.